Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TREND-FL: Tafasitamab and Rituximab to Enhance Outcomes in Patients With Newly Diagnosed Follicular Lymphoma

NCT07731789 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT07731789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07731789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TREND-FL: Tafasitamab and Rituximab to Enhance Outcomes in Patients With Newly Diagnosed Follicular Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 29, 2032
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

classic follicular lymphoma, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma